
    
      This research study is a Phase 2 clinical trial. It will test the efficiency and safety of an
      investigational drug f Irinotecan,Oxaliplatin, and S1, with the goal of determining the OS of
      advanced pancreatic adenocarcinoma..

      Subjects must have a newly diagnosed stage 4 untreated metastatic pancreatic ductal cancer
      and meet all inclusion/exclusion criteria.

      Treatment consists of treatment with Irinotecan 165mg/m2, Oxaliplatin 85mg/m2 on day 1, and
      S1 40mg orally on day 1-14, every 21 days each cycle. Treatment will be administered until
      untolerable toxicities or progression or subject death, or either the subject or sponsor
      discontinues the study.
    
  